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Effects of dexamethasone on posterior capsule opacification-like changes in a 
rat lens explant model 
Abstract 
Purpose: Many patients whose sight is initially restored by cataract surgery eventually suffer secondary 
loss of vision because of posterior capsule opacification (PCO; after-cataract), a condition in which lens 
epithelial cells left behind at surgery become aberrant and migrate into the light path. The aim of this 
study was to determine whether dexamethasone (DEX), an anti-inflammatory agent widely used before 
and after cataract surgery, influences the behavior of lens cells under conditions relevant to PCO 
development. 
Methods: An established rat PCO model was used in which explanted epithelial cells attached to the lens 
capsule are exposed sequentially to TGFβ2 and FGF-2. Cultures with or without DEX (100 nM), and 
appropriate controls, were maintained for up to 30 days and assessed by light and scanning electron 
microscopy or immunolocalization of PCO markers (α-smooth muscle actin or fibronectin) or a marker for 
lens epithelial cell phenotype (Pax-6). 
Results: In the absence of DEX, explants become multilayered and plaques that express PCO markers 
form. Cells tend to gather up into the plaques, leaving the surrounding lens capsule denuded. Changes in 
lens cell behavior with addition of DEX included rapid formation of long, needle-like cells, less extracellular 
matrix deposited on explant surface, and plaques surrounded by a monolayer of migratory cells. 
Immunolocalization confirmed that the latter were not normal lens epithelial cells. 
Conclusions: Lens cell behavior in this PCO model was significantly affected by inclusion of DEX, 
highlighting the possibility that its use as an anti-inflammatory at the time of cataract surgery may 
influence PCO development. 
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 Cataract, or loss of lens transparency, is a leading cause
of blindness. Cataract associated with aging is by far the most
common form, with prevalence rising from about 25% to 100%
between the ages of 60-69 and 90+ years [1,2]. At present the
only treatment available is surgery. The preferred procedure
involves removing a circular, anterior portion of the thick cap-
sule that encloses the lens, breaking up and removing the fi-
ber mass it contains, and placing a synthetic lens implant (IOL)
into the empty capsular “bag”. However, lens epithelial cells
that are left behind during this procedure can become abnor-
mal, multiply, and spread forming opacities that consist of
multilayered fibrotic plaques, strands of cells containing ab-
normally deposited extracellular matrix (ECM), or aggrega-
tions of enlarged cells (Elschnig’s pearls). This condition is
known as posterior capsule opacification (PCO) or after-cata-
ract [3-7]. Within five years of cataract surgery, some 20-40%
of patients suffer further loss of vision because of PCO [8].
Vision can be restored by Nd:YAG laser treatment, but the
procedure is not without risk to sight and adds substantially to
the costs of treating cataract [4]. New technology IOLs, state
of the art equipment and highly skilled surgeons are helping
to reduce the incidence of PCO, but these are not available to
everyone, especially in the developing world where cataract
is a major health problem [4]. Prevention or reduction of the
severity of PCO thus remains an important goal.
Many studies now point to transforming growth factor-
beta (TGFβ) as a key player in early events associated with
the development of PCO and certain forms of naturally occur-
ring human cataract, a possibility first highlighted by the find-
ings of Liu et al. [9]. As reviewed elsewhere [10], both in
vitro and in vivo, TGFβ rapidly induces lens epithelial cells
from humans, rats and other mammalian species to undergo
epithelial-mesenchymal transition. The resulting fibroblastic
and spindle-like myofibroblastic cells express proteins not nor-
mally found in lens cells, such as α-smooth muscle actin, types
I and III collagen, fibronectin, desmin, and tenascin. Such
changes characteristically occur during human PCO develop-
ment.
Results obtained recently using a rat lens epithelial ex-
plant model suggest that fibroblast growth factor (FGF) may
also play a role in PCO development [10]. In this model, ex-
plants were exposed sequentially to TGFβ2 and FGF-2, both
of which are potentially available to lens cells in situ follow-
ing cataract surgery [10]. Addition of FGF-2 not only pro-
moted the long term survival of aberrant TGFβ affected cells,
which otherwise rapidly undergo apoptosis [11], but also in-
duced a variety of responses typically associated with PCO
development. Many of these had not previously been gener-
ated in a PCO model in vitro.
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PCO-like changes in this model [10] included the retrac-
tion of cells into multilayered strands or plaques with abnor-
mal deposition of ECM, a feature of the fibrotic form of PCO,
and the formation of plaques of cells that resemble the
Elschnig’s pearls that are a feature of “pearl-like” PCO. In
addition, these cells expressed α-smooth muscle actin, type I
collagen, and fibronectin, as in PCO. Such responses were
generated using concentrations of TGFβ2 and FGF-2 ranging
from 25-100 pg/ml and 20-100 ng/ml, respectively. Other
growth factors tested (insulin-like growth factor, platelet-de-
rived growth factor, epidermal growth factor, and hepatocyte
growth factor), did not promote survival of TGFβ affected
cells [10].
Previously, FGF had been shown to stimulate prolifera-
tion and spreading of lens cells across the posterior capsule
towards the visual axis in cultured human lens “capsular bags”
[12], obtained by carrying out sham cataract surgery on eyes
post mortem, and to exacerbate TGFβ induced subcapsular
cataract formation in cultured rat lenses [13].
Surgery for cataract generates short term inflammation,
which is routinely controlled by applying anti-inflammatory
drugs both before surgery and for 2-6 weeks after surgery.
Glucocorticoids are widely used for this purpose [14,15].
Human, rabbit, bovine, mouse, and rat lens epithelial cells have
been shown to express glucocorticoid receptors [16-19]. Fur-
ther, even a single application of a glucocorticoid containing
eye drop is sufficient to generate potentially effective concen-
trations of these drugs in the aqueous [20,21], the ocular fluid
to which residual lens epithelial cells are directly exposed af-
ter cataract surgery. It is thus important to establish whether
the use of this drug influences PCO development.
Using the rat lens explant model described above, we have
investigated the effects of including dexamethasone (DEX), a
widely used glucocorticoid, in the medium at a clinically rel-
evant concentration during the development of PCO-like
changes. Such changes were generated by culturing for one
day with TGFβ2 then with FGF-2 for up to 30 days. The ef-
fects of including DEX throughout the culture period were
assessed by light and scanning electron microscopy and by
immunolocalization of two proteins that typically appear in
lens cells undergoing epithelial-mesenchymal transition dur-
ing PCO development and Pax-6, a marker for lens epithelial
phenotype.
METHODS
 Recombinant human TGFβ2 (Genzyme, Cambridge, MA) and
FGF-2 (PeproTech, Rock Hill, NJ) were used as described
previously [10]. Cell culture grade DEX was purchased from
Sigma (St Louis, MO). The following antibodies were used;
mouse α-smooth muscle actin antibody (Sigma; clone 1A4),
goat anti-rat fibronectin (Calbiochem, La Jolla, CA), Pax-6
antibody (Covance, Berkeley, CA), Alexa 488 conjugated anti-
mouse antibody (Molecular Probes, Eugene, OR), and Cy3
conjugated anti-goat or anti-rabbit antibody (Zymed, San Fran-
cisco, CA).
Lens epithelial explants were prepared from 19-21 day-
old Wistar rats using serum free medium M199 containing
bovine serum albumin and antibiotics (control medium), as
described [10,11]. In the basic model (TGFβ/ GF treated
group), explants were exposed to TGFβ for one day then to
FGF throughout culture. When all explants had been set up,
medium was replaced with control medium, 50 pg/ml TGFβ
was added, and explants were cultured at 37 °C in 5% CO
2
.
One day later, the TGFβ-containing medium was discarded
and replaced with 1 ml control medium containing 20 ng/ml
FGF. Explants were maintained in culture for up to 30 days,
with change of medium and re-addition of FGF every 4-6 days.
DEX treated explants received DEX at a final concentration
of 100 nM on day 0 immediately prior to the addition of TGFβ
and again on day 1, then at each change of medium unless
otherwise indicated. TGFβ and/or FGF and DEX were omit-
ted from controls.
Explants were monitored by phase contrast microscopy
during culture then fixed in 100% ethanol (for Pax-6 localiza-
tion) or Carnoy’s fixative (ethanol:acetic acid, 3:1 v/v) and
stored in 70% ethanol. Some explants were embedded in par-
affin and sectioned serially perpendicular to the lens capsule
and central sections were stained with hematoxylin and eosin.
Whole mounts were used for immunolocalization of markers
for PCO-like change (α-smooth muscle actin and fibronectin,
double labeling) or Pax-6, visualized using appropriate Alexa
488 or Cy3 conjugated secondary antibodies, counterstained
with Hoechst dye and mounted using Vectashield, as described
[10,13]. Under these conditions, immunoreactivity was ab-
sent from controls in which antibodies were replaced with
corresponding non-immune IgGs. For SEM, whole mounts
were dehydrated with 100% ethanol, critical point dried, gold
coated, and viewed using a Philips XL30 scanning electron
microscope.
RESULTS
Morphological changes induced by DEX:  As described pre-
viously [10,11], in the absence of FGF, TGFβ at the concen-
tration used in the present study induced the formation of
spindle-like cells beginning on about day 2 of culture. These
cells, and surrounding cells, subsequently undergo apoptotic
cell death. They exhibit extensive cell surface blebbing, then
round up and die leaving the underlying lens capsule denuded
[10,11,22]. A typical TGFβ treated explant and a correspond-
ing control explant cultured without growth factors are shown
in Figure 1A,B. Loss of cells makes it difficult to discern the
presence of spindle-like cells at this stage of culture. In con-
trast, TGFβ/FGF treated explants remained well covered with
viable cells including occasional spindle-like cells (Figure 1C)
[10]. In TGFβ/FGF/DEX treated explants, however, numer-
ous spindle-like or needle-like cells were present in parallel
arrays throughout the explant (Figure 1D). These cells, which
were much more regularly arranged than the spindle-like cells
observed in explants treated with TGFβ/ GF in the absence
of DEX (compare Figure 1C and Figure 1D), were clearly
distinguishable between days 4-6 but not at later stages of
culture. Further, the spindle-like cells in TGFβ/ GF treated
explants, with or without DEX, differed from spindle-like cells
induced by TGFβ alone in that, generally, they did not de-
©2004 Molecular VisionMolecular Vision 2004; 10:728-37 <http://www.molvis.org/molvis/v10/a88>
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velop cell surface blebbing or other morphological changes
associated with TGFβ induced cell death (Figure 1B-D). Cells
in corresponding explants cultured in control medium only or
with FGF or DEX alone tended to remain in the cobblestone
array typical of the normal lens epithelium (as in the explant
depicted in Figure 1A), although some cell loss was noted
under these conditions in explants that were initially poorly
covered with cells (not shown).
Inclusion of DEX also influenced the outcome in TGFβ/
FGF treated explants cultured for a longer period (Figure 2).
In the absence of DEX, where cell coverage was initially
patchy, cells quickly began to gather up into plaques or thick-
ened mounds, while in regions that remained well covered
with cells, retraction of cells into plaques and mounds began
on about day 10-15, as described previously [10]. Thus, at the
end of the culture period, patches of denuded lens capsule were
visible between cellular regions, which were multilayered and
contained swollen cells (Figure 2A,C,E). In contrast, when
DEX was included, retraction of cells from the capsule in well-
covered regions did not occur and such explants remained
covered with cells at the end of the culture period (Figure
2B,D,F). While generally arranged in multilayers, these cells
were sometimes present in a monolayer (Figure 2D) and ap-
peared to be much smaller than in corresponding explants that
did not receive DEX (Figure 2E,F). Whether or not DEX was
included, explants showed more extensive thickening in the
peripheral region than in the central region (Figure 2C-F). In
the presence of DEX, in regions where cells were initially
present in isolated patches, plaques formed surrounded by a
monolayer of cells. In corresponding explants cultured with
DEX alone (Figure 2G,H), and in explants cultured in control
medium only (not shown), cells were present in a cuboidal
monolayer as in the normal lens epithelium.
Similarly, SEM revealed marked differences between
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Figure 1. Effect of dexamethasone on cell morphology: phase contrast microscopy.  Explants were cultured in control medium (A) or with 50
pg/ml TGFβ2 for 1 day (B-D), then medium was replaced and 20 ng/ml FGF-2 was added to some cultures (C,D). In D only, 100 nM DEX was
included on day 0 and day 1. Explants were cultured for a total of 5 (A,B) or 6 (C,D) days, then photographed. Cells in control explants,
cultured without growth factors or DEX, tended to remain in cobblestone arrays typical of the normal lens epithelium, as shown in A.
Treatment with TGFβ only (B) resulted in extensive cell surface blebbing (arrowheads) associated with loss of cells from the lens capsule
(asterisk) and wrinkling of the lens capsule (arrow). Adding FGF on day 1 largely prevented these changes (C,D). Under the latter conditions,
in the absence of DEX (C), explants remained well covered with cells, which included occasional spindle-like cells (arrows). However,
inclusion of DEX (D) resulted in the formation of numerous parallel arrays of spindle-like cells (arrows) throughout the explant. The bar
represents 30 µm in A and B and 75 µm in C and D.
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TGFβ/FGF treated explants cultured for 30 days in the pres-
ence or absence of DEX (Figure 3). Explants cultured without
DEX or with DEX are shown at relatively low magnification
in Figure 3A and Figure 3B, respectively. In each case, plaque
formation occurred; however, only the explant exposed to DEX
contained migratory cells extending in a monolayer from the
base of the plaque. In some explants exposed to DEX this
monolayer of cells was quite extensive (Figure 4D, Figure
5A,C). The surface of the explant cultured without DEX shown
in Figure 3A, was covered by a thick web of ECM-like mate-
rial, which obscured the cells (Figure 3C,E). In another ex-
plant from the latter treatment group, ECM-like material was
present only in occasional patches on the surface of the cells,
many of which were flattened and elongated and exhibited
tongue and flap processes, like cells undergoing FGF induced
fiber differentiation (Figure 3G) [10,23]. In contrast, in ex-
plants cultured with DEX, there was little or no deposition of
ECM-like material on the surface of the cells, which exhib-
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Figure 2. Effect of dexamethasone on cell morphology: hematoxylin and eosin stained sections.  Lens epithelial explants were treated with
TGFβ then FGF without addition of DEX (A,C,E) or with addition of DEX (B,D,F), as described in the legend to Figure 1, or treated in
parallel with DEX alone (G,H). Medium was replaced 5 days after addition of FGF and every 4-6 days thereafter, with re-addition of FGF (A-
F) and/or re-addition of DEX (B,D,F-H). At the end of the culture period explants were fixed, embedded and sectioned transversely. Low
power images of sections are shown in A and B, with labeled boxes to indicate the regions shown at higher magnification in C,D,E, and F. In
TGFβ/FGF treated explants in the absence of DEX, explants exhibited multilayering and extensive enlargement of cells (C,E) and, between
cellular aggregates, regions of denuded lens capsule were visible (C, arrow). When DEX was included, multilayering also occurred but there
appeared to be less cell enlargement and most of the lens capsule remained covered with cells (B,D,F), although in some regions only a thin
monolayer of cells was present (D, arrow). With or without DEX, the explants were thicker in the peripheral region (E,F) than in the central
region (C,D). In contrast, explants cultured in parallel with DEX alone generally remained covered with a monolayer of cuboidal cells in both
the central (G) and peripheral (H) region, as in the normal lens epithelium. The bar represents 250 µm in A and B and 50 µm in C-H. The
peripheral region (Per) and the central region (Cn) of the explants are labeled.
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ited a variety of unusual profiles (Figure 3D,F,H,I). These were
quite different from the cobblestone arrays of cells observed
in lens epithelial explants cultured in control medium (not
shown) [10,23].
Immunolocalization studies:  Immunolocalization was
carried out to determine whether the monolayers of cells
present around the base of plaques in TGFβ/FGF/DEX treated
explants were normal lens epithelial cells or whether they were
aberrant cells. First, explants cultured for 30 days with TGFβ
then FGF, with or without inclusion of DEX, were assessed
by immunolocalization of α-smooth muscle actin and
fibronectin (Figure 4). These proteins, which are not present
in normal lens epithelial cells, are found in PCO and are in-
duced by exposing lens cells to TGFβ. Cells present in the
multilayered plaques that formed in TGFβ/ GF treated ex-
plants exhibited reactivity for both α-smooth muscle actin and
fibronectin, whether DEX was absent or whether it was in-
cluded throughout the entire culture period (Figure 4A-F), al-
though reactivity for α-smooth muscle actin appeared weaker
when DEX was included (Figure 4B,E). However, no reactiv-
ity for either of these proteins was detectable in the continu-
ous monolayer of attenuated cells surrounding the plaques in
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Figure 3. Effect of dexamethasone
on cell morphology: SEM.  Lens
epithelial explants were treated
with TGFβ then FGF without ad-
dition of DEX (A,C,E,G) or with
addition of DEX (B,D,F,H,I), as
described in the legend to Figure
2, then processed for SEM. Aster-
isks indicate regions of denuded
lens capsule. In these TGFβ/ GF
treated explants, both in the ab-
sence of DEX (A) and the pres-
ence of DEX (B), thick plaques of
cells formed during culture. In the
presence of DEX, however, a
monolayer of attenuated cells
formed, extending from the base
of the plaque across the lens cap-
sule (B, arrowhead). The general
topography of these explants was
also markedly different (C,D). Ex-
amination at higher magnification
revealed that the explant cultured
without DEX was covered with a
thick web of ECM-like material,
which completely obscured the
cellular surface (E). In another
TGFβ/FGF treated explant cul-
tured without DEX (G), ECM-like
material was present in scattered
patches (arrow), and flattened,
elongated cells were visible,
which exhibited occasional
tongue and flap-like, interdigitat-
ing processes at their margins (G,
arrowheads). In contrast, the DEX
treated explant shown in B and D
exhibited only very sparse depo-
sition of ECM-like material (F),
wh ile extensive regions of an-
other explant in this treatment
group appeared completely de-
void of surface ECM (H,I). The
cells in the DEX treated explants
exhibited diverse and unusual
morphologies (F,G,H). The bars
represent 50 µm in A-D and 20 µm
in E-I.
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the DEX treated explants (Figure 4E,F).
Removing DEX from the culture medium during the last
20 days of culture resulted in markedly enhanced reactivity
for α-smooth muscle actin in the plaques (Figure 4H), com-
pared with cultures that received DEX continuously (Figure
4E), and reactivity became detectable in the surrounding mono-
layer of cells (Figure 4H). However, reactivity for fibronectin
in the plaques was similar whether DEX was removed (Fig-
ure 4I) or present continuously (Figure 4F) and remained un-
detectable in the monolayer of cells (Figure 4I). The only ex-
ogenous growth factor the explants were receiving over the
last 20 days of culture in this case was FGF. It has previously
been shown that culturing freshly prepared rat lens epithelial
explants with FGF alone, at the concentration used in the
present study, tends to suppress α- mooth muscle actin ex-
pression rather than induce it [10]. Thus it is highly likely that
the cells in the monolayer that formed in TGFβ/ GF/DEX
treated explants were already abnormal prior to the removal
of DEX on day 10.
Immunolocalization was also used to assess whether Pax-
6 was expressed by cells in TGFβ/ GF/DEX treated explants,
particularly in the monolayered regions. This transcription
factor, which is required for proper eye development, is ex-
pressed by normal lens epithelial cells but not mature fiber
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Figure 4. Immunolocalization of α-smooth muscle actin and fibronectin in cell cultures.  Lens epithelial explants were cultured with TGFβ
then FGF, without DEX (A-C) or with addition of DEX on day 0 and at each change of medium throughout the entire culture period (D-F), as
described in the legend to Figure 2. Other explants (G-I) were treated with TGFβ/FGF/DEX as for D-F but DEX treatment was discontinued
from day 10 of culture onwards. Explants were fixed as whole mounts and processed for immunolocalization of α-smo th muscle actin
(B,E,H; green) and fibronectin (C,F,I; red) by a double labeling technique, with Hoechst counterstaining of nuclei (A,D,G). In all treatment
groups, reactivity for both α-smooth muscle actin (B,E,H) and fibronectin (C,F,I) was detected wherever cells had become multilayered and
formed into plaques (asterisks in A,D,G). Reactivity for α-smooth muscle actin was relatively weak in plaques in explants treated continu-
ously with DEX (E) but particularly strong in explants in which DEX treatment was discontinued at 10 days (H). Monolayered regions of cells
adjacent to plaques were present only in explants that received DEX, whether DEX was present continuously (D, arrowheads) or discontinued
at 10 days (G, arrowheads). In the former treatment group, no reactivity for the PCO markers was present in the monolayered cells (E,F),
while in the latter group, reactivity for α-smooth muscle actin was readily detectable in these cells (H, arrowheads) but reactivity for fibronectin
was not (I). The bar represents 80 µm.
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cells [24-26] and thus serves as a marker for lens epithelial
cell phenotype. It has been shown previously that, in the ab-
sence of DEX, cells in TGFβ/FGF treated explants lose Pax-6
expression within 5 days [10]. In TGFβ/FGF/DEX treated
explants cultured for 30 days, there was no detectable Pax-6
expression either in the plaques or in the monolayer of cells
surrounding them (Figure 5). This represents further evidence
that the cells, even those that remained in a monolayer, were
not normal lens epithelial cells. Frequent monitoring of TGFβ/
FGF/DEX treated explants by phase contrast microscopy dur-
ing culture revealed that many of the cells at the leading edge
of flattened, monolayered regions exhibited the characteris-
tics of actively migrating cells. They became attenuated and
developed lamellae (Figure 5C) and appeared to spread out
across the adjacent bare lens capsule as culture proceeded.
Thus, in TGFβ/FGF treated explants, whether DEX was
included or not, all cells lost their epithelial cell phenotype, as
evidenced by loss of Pax-6 expression, while cells in thick-
ened regions of the explants began expressing the
myofibroblast/PCO marker α-smooth muscle actin. However,
a striking feature of TGFβ/FGF/DEX treated explants that was
not observed in corresponding TGFβ/ GF treated explants was
the monolayer of aberrant, apparently migratory, cells that
formed at the base of thickened plaque-like regions and spread
out across the lens capsule. Moreover, the cells in this mono-
layer were “PCO-like” in that they were capable of express-
ing α-smooth muscle actin, which became detectable upon
removal of DEX.
DISCUSSION
 In the rat lens explant model used in the present study ex-
plants cultured with TGFβ then FGF without addition of DEX
exhibited many features of PCO development over the 30 day
culture period, as reported previously [10]. Cells became mul-
tilayered and tended to gather up into plaques, leaving the sur-
rounding lens capsule denuded. These plaques, which arose
quite abruptly from the lens capsule, were covered with a thick
web of ECM-like material. In addition, cells underwent epi-
thelial-mesenchymal transition, as evidenced by expression
of α-smooth muscle actin and fibronectin, non-lens proteins
that are typically associated with human PCO.
In this model, significant changes in lens cell behavior
occurred when DEX was included throughout the culture pe-
riod. These included rapid formation of long, needle-like cells
early in the culture period and a reduction in the overall extent
of thickening of the explant over time, which was associated
with a decreased tendency for the lens capsule to become de-
nuded as plaques formed. However, when plaques did form
jacent to regions of denuded lens capsule, they were gener-
ally surrounded by a monolayer of migratory cells. These did
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Figure 5. Lack of Pax-6 expression in explants cultured with TGFβ, FGF, and DEX.  Explants were cultured with TGFβ then FGF with
inclusion of DEX throughout the entire culture period (A,B,C), as described in the legend to Figure 2. They were then photographed by phase
contrast microscopy (C) or fixed as whole mounts and processed for immunolocalization of Pax-6 (B) with Hoechst counterstaining of nuclei
(A). An explant cultured without addition of growth factors for 7 days and processed in parallel provided a positive control for Pax-6 expres-
sion (D, Hoechst dye; E, Pax-6). In TGFβ/FGF/DEX treated explants multilayered plaques formed (A, asterisk indicates plaque); these were
associated with a monolayer of cells radiating out from the base of the plaque onto the lens capsule. Pax-6 reactivity was not detectable in
either the plaque or the surrounding monolayer of cells (B), whereas cells in the positive control exhibited strong nuclear reactivity for Pax-6
under these localization conditions (D,E). A phase contrast micrograph (C) of an explant analogous to that depicted in A and B shows a
monolayer of cells spreading out from the base of a plaque (asterisk); cells at the leading edge have developed lamellae (arrowhe ds), a
characteristic of actively migrating cells. The bar represents 50 µm in A, B, D, and E and 40 µm in C.
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not appear to be normal lens epithelial cells in that they did
not express the lens epithelial phenotype marker Pax-6. Fur-
ther, although α-smooth muscle actin reactivity could not be
detected in the monolayered cells when DEX was included
throughout the entire culture period, reactivity for this marker
for PCO-like change did become detectable when DEX was
removed late in the culture period. The mechanism(s) under-
lying these effects of DEX have not yet been elucidated. Of
interest in this context, however, is the finding that TGFβ2
enhances synthesis of prostaglandin E2 by explanted human
lens epithelial cells obtained at cataract surgery [27], whereas
an established general mechanism of action of DEX is inhibi-
tion of the synthesis of the prostaglandin precursor arachi-
donic acid [28].
The concentration of DEX used in the present study, 100
nM (39 ng/ml), has been shown to be effective in inducing
biological effects in many studies in vitro of cells from the rat
and other species [29-32], including lens epithelial cells [33].
It also approximates concentrations of DEX achieved in the
aqueous in the anterior chamber of the eye following admin-
istration of DEX eye drops as at cataract surgery. After appli-
cation of a single drop of DEX alcohol (Maxidex™) to hu-
man subjects, mean peak concentrations in the aqueous of 31
ng/ml [20] and 60 ng/ml [34] have been reported. A mean
concentration in the aqueous of 31 ng/ml was also reported in
a study in which patients received repeated doses of DEX di-
sodium phosphate [35].
In previous studies, DEX has been shown to influence
lens epithelial cells in vitro in various ways. It enhances αB-
crystallin expression of epithelial cells in rat lens explants [36]
and alters expression of basement membrane proteins in cul-
tured bovine cells [33]. These effects were achieved using 100-
500 nM DEX. In other studies, which showed altered cadherin
expression in cultured rat lenses [37] and inhibition of lens
epithelial cell proliferation [38] in response to DEX treatment,
higher concentrations were used, 5 µM and 250 µM, respec-
tively. In vivo, treatment of rabbits with DEX eye drops as
used for cataract surgery has been shown to induce metabolic
changes and reduce glutathione levels in the lens [39].
The causative relation between long term corticosteroid
therapy and the induction of cataractous changes in the intact
lens is well established, albeit not well understood [40]. Less
attention has been paid to the possibility that glucocorticoids
such as DEX, when administered at the time of cataract sur-
gery, may influence the behavior of the residual lens cells from
which PCO arises. There are two studies in which the effect
of DEX on PCO development has been investigated in nor-
mal rabbits subjected to a cataract surgery procedure. In the
study of Wallentin et al. [41], rabbits received DEX eye drops
or no treatment for one month post surgery. When PCO total
wet weight was measured four weeks after ceasing treatment,
there was no difference between DEX treated and untreated
groups. A similar result was obtained when rabbits were treated
with large doses of prednisolone and DEX prior to and for 12
h after surgery [42]. Note that this method of PCO assessment
did not provide any information about possible between treat-
ment differences in specific responses of cells and their loca-
tion relative to the light path. Furthermore, the assessment was
carried out at only one time point at a relatively late stage in
PCO development, which occurs very rapidly in the rabbit
[43]. In another such study that reported reduction of PCO by
DEX [44], lens cells were exposed directly during surgery to
a much higher dose of DEX than is normally applied to the
eye surface to control inflammation after cataract surgery.
In the present study, DEX at a clinically relevant dose
was shown to influence the behavior of lens cells undergoing
PCO-like changes in ways that could influence visual outcome
if they occurred in a human patient. For example, it could be
argued that a reduction in the thickness of the cellular layer
and prevention of deposition of ECM-like material, as observed
in the presence of DEX in the rat model, would reduce opaci-
fication and hence improve visual outcome. Formation of
opaque multilayered plaques and aggregations of cells and
abundant deposition of ECM by aberrant cells are thought to
contribute significantly to visual impairment in human PCO
[3-5]. On the other hand, if DEX induced the formation of a
monolayer of viable, aberrant cells spreading out from the base
of PCO-like plaques, as noted in the present study, it could be
argued that visual outcome would be worsened because of an
increased risk that abnormal cells would reach the visual path-
way. Interestingly, regions of monolayered cells expressing
α-smooth muscle actin occur in human PCO [45,46], remi-
niscent of the monolayer of cells in Figure 4H. In the latter
case, the explant received DEX together with FGF for the first
10 days of culture then FGF only, a treatment that mimics
discontinuation of DEX treatment 1-2 weeks post cataract
surgery.
Because of the remarkable similarities between lens epi-
thelial cells from rats and humans in terms of their responses
to the cataractogenic effects of TGFβ, useful information about
human PCO can be obtained using rat models. However, di-
rect extrapolation from the results reported in this study to the
development of human PCO under clinical conditions, along
the lines suggested above, is problematic. First, it cannot be
assumed that dexamethasone will produce cellular responses
in human lens cells identical in every respect to those observed
in the rat model, although it is likely that it will have some
effect on them, given the presence of glucocorticoid receptors
on human lens cells [16-18] and the plethora of known effects
of dexamethasone on cells in general. More importantly, the
behavior of lens cells during human PCO development in situ
and their responses to the presence of DEX may be signifi-
antly affected by the complex assortment of growth factors,
cytokines and other effector substances present in their envi-
ronment post cataract surgery. Clinical trials designed to test
the effects of DEX (or other glucocorticoids) on PCO devel-
opment in vivo, under conditions typically encountered dur-
ing and after cataract surgery, thus offer a distinct advantage
over studies in vitro in either rat or human models.
While the literature contains reports of numerous clinical
trials of the effectiveness of DEX in prevention of inflamma-
tion [15], follow-up assessment of PCO development has rarely
been included. Only a few relevant reports appear in the lit-
erature, all published recently [47-49]. In the first of these
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[47], three treatment groups were compared; patients received
DEX, diclofenac (a non-steroidal anti-inflammatory drug), or
placebo (saline). No significant difference between the groups
was detected 2 years after surgery, in terms of the proportion
of patients requiring laser capsulotomy for PCO (15-18%).
After 4 years, however, capsulotomy rates for DEX, diclofenac
and placebo were 47, 63, and 32%, respectively. Only the dif-
ference between diclofenac and placebo reached statistical sig-
nificance, however. This study is thus noteworthy in that it
indicates that at least one drug used to control inflammation
at the time of cataract surgery may be associated with an in-
creased incidence of PCO requiring laser treatment. In a sec-
ond study by this group [48], the same anti-inflammatory drugs
were used at lower dosages and PCO development was as-
sessed by both image analysis and capsulotomy rate. The three
treatments again gave similar results at 2 years, but PCO evalu-
ation beyond 2 years was not included. In these studies, the
number of patients per group was relatively small, less than
60 [47] or 40-45 [48].
In another study, in which no placebo group was included,
the effects of the glucocorticoid betamethasone were compared
with diclofenac and PCO development was assessed 3 years
post surgery by grading of photographs as well as capsulotomy
rate [49]. Here PCO outcome appeared to be worse in
betamethasone treated patients. For example, in the
betamethasone and diclofenac groups, respectively, the over-
all incidence of PCO was 70% and 55%, with a 30% and 15%
incidence of severe PCO. However, again only a small num-
ber of patients was evaluated (20-30 per group) and apparent
differences did not reach statistical significance.
In summary, using a rat lens explant model for PCO, the
effects of DEX have been investigated at a concentration and
over time periods that lens epithelial cells are likely to en-
counter following cataract surgery. Aspects of lens cell be-
havior highly relevant to PCO development were clearly af-
fected by the presence of DEX. As this rat model closely mim-
ics cellular events in PCO development in humans and other
species [10] and as human lens epithelial cells express tran-
scriptionally active glucocorticoid receptors [18,19], it seems
likely that glucocorticoids exert effects on residual lens cells
left behind at cataract surgery.
Although the results of the present study in the rat model
point to various ways in which PCO development may be in-
fluenced by DEX, it is not clear whether analogous effects
occur in the clinical situation. Limited clinical trials carried
out to date have provided equivocal results, leaving this ques-
tion unresolved. The present study thus highlights both the
possibility that anti-inflammatory drugs used routinely at the
time of cataract surgery may influence PCO development and
the need for more detailed clinical evaluation of this issue.
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